Anbc, Inc. (SYUP) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.02 means the share price is 0.02 times one year of earnings per share; the S&P 500 usually sits near 20-25.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAnbc, Inc. (SYUP) trades at $0.0003. Anbc, Inc., operating as Shanghai Yutong Pharma, develops, manufactures, and commercializes traditional Chinese medicines and biological pharmaceuticals. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SYUP: SYUP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SYUP against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
SYUP: 2/2 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Anbc, Inc. (SYUP) Healthcare & Pipeline Overview
Shanghai Yutong Pharma (SYUP) focuses on traditional Chinese herbal medicines and biological pharmaceuticals, offering products like Qilisheng and Qi-ju-di-huang. Operating in the People's Republic of China, the company distributes through wholesale channels, emphasizing immune support, organ protection, and symptom relief in the specialty and generic drug market.
What Is the Investment Thesis for SYUP?
The company's focus on traditional herbal medicines and biological pharmaceuticals caters to a specific segment within the Chinese healthcare market. Growth catalysts include expanding distribution networks and introducing new products within its existing therapeutic areas. However, the company faces risks associated with operating on the OTC market, including potential liquidity constraints and disclosure requirements. The company's beta of -6.47 suggests a low correlation with the overall market, potentially offering diversification benefits. The company's P/E ratio is 0.02.
Based on FMP financials and quantitative analysis
SYUP Key Highlights
Profit Margin of 41.1% indicates strong profitability in the traditional Chinese medicine market.
- Gross Margin of 49.1% reflects efficient cost management in the production of herbal medicines and biological pharmaceuticals.
- Beta of -6.47 suggests a low correlation with the overall market, potentially offering diversification benefits.
- The company operates in the growing Chinese pharmaceutical market, which is driven by increasing healthcare spending and an aging population.
- P/E ratio of 0.02 indicates a potentially undervalued stock.
Who Are SYUP's Competitors?
SYUP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AVCNF Avicanna Inc. | $0.08 | 0.00% | $10.6M | 529-signal |
| PLNH Planet 13 Holdings Inc. | $0.13 | -7.14% | $42.7M | 429-signal |
| DBCCF Decibel Cannabis Company Inc. | $1.27 | -3.39% | $49.0M | 459-signal |
| ZYBT Zhengye Biotechnology Holding Limited | $1.59 | +1.27% | $75.4M | 465-pillar |
| CWBHF Charlotte's Web Holdings, Inc. | $0.33 | -3.93% | $88.4M | 519-signal |
| AAWH Ascend Wellness Holdings, Inc. | $0.49 | +1.36% | $98.7M | 439-signal |
| BGM BGM Group Ltd. | $0.28 | +0.92% | $105M | 455-pillar |
| MEDXF Medexus Pharmaceuticals Inc. | $3.59 | -1.40% | $114M | 479-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are SYUP's Key Strengths?
Established presence in the Chinese pharmaceutical market.
- Proprietary formulations of traditional Chinese medicines.
- High profit margin of 41.1%.
- Gross margin of 49.1%.
What Are SYUP's Weaknesses?
Reliance on the Chinese market.
- Limited product diversification.
- OTC listing may limit access to capital.
- Unknown disclosure status.
What Could Drive SYUP Stock Higher?
Potential new product launches in the traditional Chinese medicine market.
- Expansion of distribution network within China.
- Strategic partnerships with other pharmaceutical companies.
- E-commerce and online sales initiatives.
- Potential international expansion into new markets.
What Are the Key Risks for SYUP?
Competition from other pharmaceutical companies in China.
- Regulatory changes in the Chinese pharmaceutical market.
- Fluctuations in the Chinese economy.
- Product liability claims.
- Limited liquidity due to OTC listing.
What Are the Growth Opportunities for SYUP?
- Expanding Distribution Network: Anbc, Inc. can grow by expanding its distribution network within China, targeting underserved regions and increasing its presence in existing markets. The Chinese pharmaceutical distribution market is estimated to be worth billions of dollars, offering significant potential for growth. Timeline: Ongoing.
- New Product Development: The company can invest in research and development to introduce new traditional Chinese medicines and biological pharmaceuticals, addressing unmet medical needs and expanding its product portfolio. The market for herbal medicines is growing, driven by increasing consumer awareness and acceptance. Timeline: Ongoing.
- Strategic Partnerships: Anbc, Inc. can form strategic partnerships with other pharmaceutical companies, research institutions, and distributors to leverage their expertise, resources, and market access. Partnerships can accelerate product development, expand market reach, and enhance competitiveness. Timeline: Ongoing.
- E-commerce and Online Sales: The company can establish an online presence and sell its products through e-commerce platforms, reaching a wider customer base and increasing sales. The online pharmaceutical market in China is growing rapidly, driven by increasing internet penetration and consumer adoption of online shopping. Timeline: Upcoming.
- International Expansion: Anbc, Inc. can explore opportunities to expand its operations and sell its products in international markets, particularly in regions with a significant Chinese diaspora and a growing interest in traditional Chinese medicine. The global market for herbal medicines is estimated to be worth billions of dollars. Timeline: Upcoming.
What Are SYUP's Competitive Advantages?
- Proprietary formulations of traditional Chinese medicines.
- Established distribution network in China.
- Brand recognition in the Chinese market.
- Expertise in traditional Chinese medicine and biological pharmaceuticals.
What Does SYUP Do?
Shanghai Yutong Pharma, Inc., also known as Anbc, Inc. (SYUP), is a pharmaceutical company based in Shanghai, China, focused on the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals. The company's origins lie in addressing the healthcare needs within China by leveraging traditional medicine practices combined with modern pharmaceutical techniques. Its product portfolio includes a range of solutions targeting various health conditions. Key products include Qilisheng, designed to enhance the immune system; Qi-ju-di-huang, an oral solution aimed at protecting the kidney and liver; and Qing-re-jie-du, an oral solution to reduce fever and relieve heat. Additionally, they offer Sheng-mai-yin for energy enhancement, Xiao-qing-long for cough relief, Shen-bao syrup for treating impotence, Ban-xia syrup for cough, and Gan-mao-zhi-ke syrup for flu symptoms. The company also provides Ban-lan-gen and Gan-mao-qing-re for cold and flu symptoms, Huang-dan-yin-chen for jaundice treatment, and Liu-shen-qu for treating vomiting and dysentery. Shanghai Yutong Pharma distributes its products through wholesale channels to distributors across the People's Republic of China.
What Products and Services Does SYUP Offer?
- Develops traditional Chinese herbal medicines.
- Manufactures biological pharmaceuticals.
- Commercializes pharmaceutical products in China.
- Offers solutions for immune support.
- Provides medicines for kidney and liver protection.
- Creates solutions for cold and flu relief.
- Distributes products on a wholesale basis.
How Does SYUP Make Money?
- Develops and manufactures traditional Chinese medicines and biological pharmaceuticals.
- Sells products to distributors on a wholesale basis.
- Focuses on the Chinese market.
- Generates revenue through product sales.
What Industry Does SYUP Operate In?
Anbc, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, which is experiencing growth in China due to increasing healthcare expenditure and demand for traditional medicines. The market is competitive, with companies like BZAMF (Biozoom Inc.), CANQF (CannTrust Holdings Inc), COTQF (Cotinga Pharmaceuticals Inc), ETAOF (Ethaverse Inc), and FORU competing for market share. The Chinese pharmaceutical market is characterized by a mix of domestic and international players, with a growing emphasis on research and development of innovative therapies and traditional medicines. Regulatory changes and healthcare reforms are also shaping the industry landscape.
Who Are SYUP's Key Customers?
- Distributors of pharmaceutical products.
- Wholesale buyers of traditional Chinese medicines.
- Healthcare providers in China.
- Consumers seeking traditional Chinese medicine solutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 51 |
| 2026-08-26 | 51 |
| 2026-08-29 | 51 |
| 2026-09-01 | 51 |
| 2026-09-04 | 51 |
| 2026-09-07 | 51 |
| 2026-09-10 | 51 |
What changed?
The score has stayed at 51.
Over the same 18 days the stock moved +50.0%.
Company Profile
Anbc, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Shanghai, CN. The company is led by CEO Wei Dong. SYUP has traded publicly since 2009.
Key Financial Metrics
Return on equity for Anbc, Inc. stands at 86.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 48.6%, showing how much profit it generates from its asset base. SYUP trades at a trailing price-to-earnings ratio of 0.02, below the Healthcare sector average of ~21.50x. A current ratio of 2.75 indicates the company holds enough short-term assets to cover its near-term obligations.
SYUP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Established presence in the Chinese pharmaceutical market.
- Proprietary formulations of traditional Chinese medicines.
- High profit margin of 41.1%.
- Gross margin of 49.1%.
Bear Case
- Reliance on the Chinese market.
- Limited product diversification.
- OTC listing may limit access to capital.
- Unknown disclosure status.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SYUP Latest News
No recent news available for SYUP.
SYUP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SYUP.
Price Targets
Wall Street price target analysis for SYUP.
SYUP MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SYUP; grades run from A+ (80-100) to F (below 30).
Leadership: Wei Dong
CEO
Wei Dong is the Chief Executive Officer of Anbc, Inc. (Shanghai Yutong Pharma). Information regarding Mr. As CEO, he is responsible for overseeing the company's strategic direction, operations, and financial performance. His leadership is crucial in navigating the competitive pharmaceutical market in China and driving the company's growth initiatives.
Track Record: Information on Wei Dong's specific achievements and milestones as CEO of Anbc, Inc. is not available. His tenure and key strategic decisions are currently unknown. Further information is needed to assess his impact on the company's performance and growth.
SYUP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Anbc, Inc. (SYUP) may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, potentially increasing investment risks.
- OTC Tier: OTC Other
- Limited liquidity due to OTC listing.
- Lack of transparency due to unknown disclosure status.
- Potential for fraud or manipulation in the OTC market.
- Limited regulatory oversight compared to major exchanges.
- Shell risk detected, indicating potential for reverse merger or other corporate restructuring.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags or warning signs, such as pending lawsuits or regulatory investigations.
- Consult with a qualified financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Operations in the pharmaceutical sector, which requires regulatory approvals.
- Focus on traditional Chinese medicine, a recognized field.
- CEO leadership with Wei Dong.
- Physical headquarters in Shanghai, China.
Anbc, Inc. Healthcare Stock: Key Questions Answered
Is SYUP a good stock?
Stock Expert AI does not rate SYUP buy, sell or hold. Anbc, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does Anbc, Inc. do?
Anbc, Inc., operating as Shanghai Yutong Pharma, develops, manufactures, and commercializes traditional Chinese herbal medicines and biological pharmaceuticals. Its product portfolio includes solutions for immune support (Qilisheng), kidney and liver protection (Qi-ju-di-huang), and cold and flu relief (Gan-mao-zhi-ke).
What are the key factors to evaluate for SYUP?
Evaluate SYUP on fundamentals, analyst consensus, and risk factors. P/E: 0.02x vs the S&P 500's ~20-25x. The company's P/E ratio is 0.02. Not financial advice.
How frequently does SYUP data refresh on this page?
SYUP's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SYUP's recent stock price performance?
Anbc, Inc. (SYUP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the Chinese pharmaceutical market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SYUP overvalued or undervalued right now?
Anbc, Inc. (SYUP) trades at 0.02x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of SYUP?
Yes, most major brokerages offer fractional shares of Anbc, Inc. (SYUP) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SYUP's earnings and financial reports?
Anbc, Inc. (SYUP) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for SYUP earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information on Wei Dong's background and track record is limited.